Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Dino's Bar & Grill -- Ignore unavailable to you. Want to Upgrade?

To: Goose94 who wrote (82483)	4/16/2020 3:37:02 PM
From: Goose94	Read Replies (1) \| Respond to of 202925

Coronavirus: Ontario researchers developing COVID-19 vaccine delivered by nasal spray Apr 16, '20 KITCHENER -- Researchers from the University of Waterloo are working on a COVID-19 vaccine that will be delivered through nasal spray, and used to both treat and immunize against the virus. While there is still plenty of testing left to be done and the work has not been peer-reviewed, the non-invasive vaccine is being designed to both treat and immunize against the virus. A news release from the university says it will work by using what's called bacteriophage, a process that allows a vaccine to replicate in bacteria that's already in the body. Roderick Slavcev, a professor in the School of Pharmacy, specializes in designing vaccines. He says that, when complete, the nasal spray will deliver "nanomedicine engineered to immunize and decreases COVID-19 infections." The school says the vaccine will actually serve two purposes: it will build immunity to the virus, and decrease the severity of an infection if someone got it. Researchers say the DNA-based vaccine will enter cells to produce what's called a VLP, or a virus-like particle, that will look like SARS-CoV-2, the virus which causes COVID-19, but will be harmless. That, they say, is what's expected to stimulate an immune response to the virus. The vaccine, which targets the nasal passage and lower respiratory tract, will also bind to receptors that the virus usually latches onto, leaving the virus with fewer sites for transmission. The process of creating the vaccine is not a simple one: two other teams are also helping with its development. Slavcev has teamed up with another School of Pharmacy professor, Dr. Emmanuel Ho, and chemical engineering professor Marc Aucoin. Ho's team is designing the nanomedication delivered by the spray, while Aucoin's team is constructing the VLP and boosting immunity. "It is the collaborative effort of our talented teams that makes this multidisciplinary project so feasible and necessarily efficient as a potential universal vaccine solution against SARS-CoV infections," says Slavcev in a news release. "To practice science with such urgency alongside such talented colleagues and their students is not only immensely educational, it is extremely rewarding." Because every element is being specifically designed, it still requires testing. Once again, the research has not yet been peer-reviewed. The University of Waterloo says it is releasing it in an effort to help inform Canada's response to COVID-19. Finnish researchers on Monday said they were to launch a study to see if gambling addiction can be treated with a fast-working nasal spray. (wakila/IStock.com) kitchener.ctvnews.ca